Cytek Biosciences, Inc. — Form 8-K Summary
Reporting event: Filed March 2, 2022, regarding actions approved February 25 and February 28, 2022. The filing concerns executive compensation under Item 5.02(e), not quarterly or annual financial results.
Business Context and Reporting Period
Cytek Biosciences, Inc. is a Delaware-based company whose common stock trades on Nasdaq under the symbol CTKB. The filing addresses fiscal-year 2022 executive compensation and cash bonuses for fiscal year 2021.
Executive Compensation and Equity Awards
| Executive | 2022 Base Salary | 2022 Target Bonus | 2021 Cash Bonus |
|---|---|---|---|
| Wenbin Jiang, Ph.D., CEO | $545,000 | 80% | $163,687 |
| Ming Yan, Ph.D., CTO | $400,000 | 50% | $134,451 |
| Patrik Jeanmonod, CFO | $385,000 | 50% | $106,492 |
The 2022 bonus program is weighted 80% to a revenue target and 20% to an EBITDA target. Funding is subject to minimum achievement thresholds, and actual awards may exceed target levels if performance exceeds predetermined goals or other goals are achieved. Individual payouts remain subject to Compensation Committee discretion.
| Executive | Stock Options | Restricted Stock Units |
|---|---|---|
| Wenbin Jiang, Ph.D. | 163,158 | 108,137 |
| Ming Yan, Ph.D. | 47,841 | 31,708 |
| Patrik Jeanmonod | 42,310 | 28,042 |
The equity awards were approved February 25 and became effective February 28, 2022. The stock options have an exercise price of $13.64, equal to the February 28 closing price, vest ratably over four years beginning January 1, 2022, and expire after 10 years unless terminated earlier. The RSUs vest over four years, beginning with 4/48 of the award on May 18, 2022, followed by 3/48 quarterly on scheduled vesting dates. Vesting is contingent on continued service.
Material Changes, Outlook, and Risks
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating results.
- The compensation program introduces revenue and EBITDA performance conditions for 2022 executive bonuses, but the filing does not disclose the numerical targets or minimum achievement thresholds.
- The awards may increase future stock-based compensation expense and share dilution; the filing text does not provide the related expense estimate or fully diluted share impact.
- Actual bonuses may differ from target amounts and are subject to performance assessments and Compensation Committee discretion.
Key Facts for Investors to Verify
- Confirm the undisclosed 2022 revenue and EBITDA targets and their minimum funding thresholds.
- Assess the accounting expense and dilution associated with the stock options and RSUs.
- Verify the final 2022 bonus payouts and performance against the stated corporate goals.
- Review subsequent filings for changes in executive employment, award vesting, or compensation arrangements.